Coffee spill

Managing dyskinesia and off time starts with a conversation with your patient and their care partner

Your patients may not tell you about dyskinesia, but that doesn't mean it isn't happening. Keep in mind that your patients may1-3:

Dyskinesia Patient behaviors graphic
Listening ear icon

Listen for cues that may indicate struggles with dyskinesia and OFF time, such as1,4-7:

  • Statements that imply compromise or settling
  • Referring to ON time negatively
  • Increases in "accident prone" behaviors
  • Describing unpredictable episodes of dyskinesia,
    ON, and OFF time
  • Difficulties with activities or hobbies
  • Feeling embarrassed in social situations
  • Care partner making comments about movement control
  • Difficulties at work
  • Based on learnings from leading organizations, including The Michael J. Fox Foundation and Parkinson’s Foundation.

Episodes of dyskinesia and off time occur unpredictably throughout the day

Multiple episodes of dyskinesia and OFF time disrupt a patient's day—starting when they wake up7

Color legend for dyskinesia video

Register for gocovri updates

Sign up to stay informed, or call 1-844-GOCOVRI and learn more about GOCOVRI in your area.

Make Selection
I authorize Adamas Pharmaceuticals, Inc., its affiliates, and its agents to communicate with me by email with information pertaining to Adamas products and services. I understand that I may revoke this authorization and choose not to receive information from Adamas by clicking the "unsubscribe" link at the bottom of the emails I receive from Adamas.

Thank you

Your registration is complete and you are now signed up to receive updates on GOCOVRI (amantadine) extended release capsules. An email will be sent to your inbox confirming your registration.

You can also call 1-844-GOCOVRI to learn more about GOCOVRI in your area.

Important Safety Information


GOCOVRI® (amantadine) extended release capsules is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.


GOCOVRI® is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2.

Warnings and Precautions

Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

Adverse Reactions

The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

View the full Prescribing Information.


GOCOVRI® (amantadine) extended release capsules is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

References: 1. Thanvi B, Nelson L, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83(980):384-388. 2. Dyskinesia. Parkinson’s Foundation website. Accessed January 22, 2019. 3. What is Parkinson’s disease? Davis Phinney Foundation website. Accessed January 22, 2019. 4. The voice of the patient: Parkinson’s disease: a series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative. Center for Drug Evaluation and Research, U.S. Food and Drug Administration; 2016. 5. Unified Dyskinesia Rating Scale (UDysRS). International Parkinson and Movement Disorder Society website. Accessed January 21, 2019. 6. Dyskinesia. The Michael J. Fox Foundation website. Accessed January 21, 2019. 7. Pahwa R, Hauser RA, Tanner CM, Johnson R, Patni R. ADS-5102 reduces on time with troublesome dyskinesia and off time throughout the waking day—time course analysis. Poster presented at: 2nd Pan American Parkinson's Disease and Movement Disorders Congress; June 22-24, 2018; Miami, FL.